FINGOLIS (Plunkett Consulting Pty Ltd)
Product name
FINGOLIS
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
172 working days (255)
Active ingredients
fingolimod hydrochloride
Registration type
New generic medicine
Indication
FINGOLIS (capsules) is indicated for the treatment of Relapsing Remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis with super imposed relapses to delay the progression of physical disability and reduce the frequency of relapse.